Search Results - "Blot, E."

A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study by Trédan, O., Follana, P., Moullet, I., Cropet, C., Trager-Maury, S., Dauba, J., Lavau-Denes, S., Diéras, V., Béal-Ardisson, D., Gouttebel, M., Orfeuvre, H., Stefani, L., Jouannaud, C., Bürki, F., Petit, T., Guardiola, E., Becuwe, C., Blot, E., Pujade-Lauraine, E., Bachelot, T.

“…Maintenance strategies beyond response or tumor stabilization with first-line chemotherapy in metastatic breast cancer (MBC) have not been extensively studied…”
Get full text

Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer by Pillé, J-Y, Li, H, Blot, E, Bertrand, J-R, Pritchard, L-L, Opolon, P, Maksimenko, A, Lu, H, Vannier, J-P, Soria, J, Malvy, C, Soria, C

“…Overexpression of RhoA in cancer indicates a poor prognosis, because of increased tumor cell proliferation and invasion and tumor angiogenesis. We showed…”
Get more information

The ELAN-ONCOVAL (ELderly heAd and Neck cancer-Oncology eValuation) study: Evaluation of the feasibility of a suited geriatric assessment for use by oncologists to classify patients as fit or unfit by Mertens, C., Le Caer, H., Ortholan, C., Blot, E., Even, C., Rousselot, H., Peyrade, F., Sire, C., Cupissol, D., Pointreau, Y., Debourdeau, P., Rolland, F., Fayette, J., Capitain, O., Sun, X., Debbah, M., Schwob, D., Boulahssass, R., Aupérin, A., Guigay, J.

Get full text

Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: Results of the randomised GEFCAPI 02 trial by Gross-Goupil, M, Fourcade, A, Blot, E, Penel, N, Négrier, S, Culine, S, Chaigneau, L, Lesimple, T, Priou, F, Lortholary, A, Kaminsky, M.C, Provencal, J, Voog, E, Bouzy, J, Laplanche, A, Fizazi, K

“…Abstract Purpose To compare the overall survival rates of good-prognosis carcinomas of an unknown primary site (CUPS) patients treated with cisplatin alone (C)…”
Get full text

Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy by BONNETERRE, J, RÉVILLION, F, DESAUW, C, BLOT, E, KRAMAR, A, FOURNIER, C, HORNEZ, L, PEYRAT, J.P

“…A pathological complete response (pCR) after neoadjuvant chemotherapy is observed in approximately 20% of breast cancer patients. A proteomic analysis was…”
Get full text

OC-0220 CHEMORADIOTHERAPY VS BIORADIOTHERAPY FOR LARYNX PRESERVATION: A GORTEC RANDOMIZED TRIAL (TREMPLIN) by Pointreau, Y, Rolland, F, Alfonsi, M, Baudoux, A, Sire, C, de Raucourt, D, Malard, O, Tuchais, C, Blot, E, Lefebvre, J.L

Get full text

Basaloid squamous cell carcinoma of the head and neck: report of 18 cases by Choussy, O, Bertrand, M, François, A, Blot, E, Hamidou, H, Dehesdin, D

“…To evaluate the clinical course and pathological characteristics of basaloid head and neck squamous cell carcinoma. Retrospective study of 18 cases of basaloid…”
Get more information

Elderly head and neck cancer (elan) study: Personalized treatment according to geriatric assessment in patients age 70 or older: First (SCCHN) unsuitable for surgery by Le Caer, H, Guigay, J, Mertens, C, Ortholan, C, Blot, E, Tao, Y, Peyrade, F, Pointreau, Y, Auperin, A

Get full text

Fatal hemoptysis in a patient with breast cancer treated with bevacizumab and paclitaxel by Philippin-Lauridant, G., Thureau, S., Ouvrier, M.-J., Blot, E.

Get full text

ASTER 70s UNICANCER phase III Trial: Can a genomic prognosticator help tailoring adjuvant systemic treatment for luminal breast carcinoma in elderly women? by Dubot, C, Bourbouloux, E, Mir, O, Kirscher, S, Rigal, O, Ferrero, J.-M, Curé, H, Blot, E, Allouache, D, Cottu, P, Romieu, G, Lefeuvre, C, Malaurie, E, Tubiana-Mathieu, N, Lacroix-Triki, M, Rollot, F, Peyro-Saint-Paul, H, Orsini, C, Bonnetain, F, Brain, E

Get full text

Impact on autonomy of biweekly docetaxel as first-line chemotherapy (CT) regimen in elderly patients with metastatic breast cancer (MBC) – A FNCLCC Gerico Group Phase II multicentre trial by Girre, V, Rousseau, F, Blot, E, Gourgou-Bourgade, S, Gouttenoire, F, Geneve, J, Delaloge, S

Get full text

Doxorubin-based adjuvant chemotherapy for elderly patients with hormone receptors negative breast carcinoma: a French geriatric oncology group (GERICO) phase II multicentric program by Debled, M, Girre, V, Mertens, C, Blot, E, Rousseau, F, Abadie, S, Uwer, L, Bourbouloux, E, Fourme, E, Gouttenoire, F, Brain, E

Get full text

Cooperation between monocytes and breast cancer cells promotes factors involved in cancer aggressiveness by BLOT, E, CHEN, W, VASSE, M, PAYSANT, J, DENOYELLE, C, PILLE, J-Y, VINCENT, L, VANNIER, J-P, SORIA, J, SORIA, C

“…In breast cancers, clinical symptoms of inflammation localised around the tumour at the time of diagnosis have been considered to have poor prognosis…”
Get full text

Apigenin – strong cytostatic and anti-angiogenic action in vitro contrasted by lack of efficacy in vivo by Engelmann, C., Blot, E., Panis, Y., Bauer, S., Trochon, V., Nagy, H.J., Lu, H., Soria, C.

“…The cancer chemopreventive agent apigenin also has strong cytostatic and anti-angiogenic effects in vitro. We now investigated its efficacy against…”
Get full text

8518 Prognostic value of the expression of SDF 1 and CXCR 4 in head and neck squamous cell carcinoma (HNSCC) by Clatot, F, Laberge-Le-Couteulx, S, Picquenot, J, Cornic, M, Choussy, O, François, A, Schultheis, D, Blot, E

Get full text

1331 Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary (CUP): a feasibility study from the GEFCAPI by Gross-Goupil, M, Loriot, Y, Lesimple, T, Merrouche, Y, Blot, E, Massard, C, Mathieu, M.C, Fizazi, K

Get full text

A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer by Delorenzi, Mauro, Farmer, Pierre, Bonnefoi, Hervé, Anderle, Pascale, Cameron, David, Wirapati, Pratyakasha, Becette, Véronique, André, Sylvie, Piccart, Martine, Campone, Mario, Brain, Etienne, MacGrogan, Gaëtan, Petit, Thierry, Jassem, Jacek, Bibeau, Frédéric, Blot, Emmanuel, Bogaerts, Jan, Aguet, Michel, Bergh, Jonas, Iggo, Richard

“…Identifying factors that influence response to cancer chemotherapy is crucial for improving its efficacy. Mauro Delorenzi and his colleagues report that a…”
Get full text

1110OPersonalized treatment according to geriatric assessment in first-line recurrent and/or metastatic (R/M) head and neck squamous cell cancer (HNSCC) patients aged 70 or over: ELAN (ELderly heAd and Neck cancer) FIT and UNFIT trials by Guigay, J, Auperin, A, Mertens, C, Even, C, Geoffrois, L, Cupissol, D, Rolland, F, Sire, C, Fayette, J, Peyrade, F, Blot, E, Debourdeau, P, Bozec, L, Capitain, O, Pointreau, Y, Brard, C, Michel, C, Schwob, D, Ortholan, C, Le Caer, H

“…Abstract Background The main challenges in patients (pts) > = 70y are to cope with the treatment benefit/risk ratio and tumor related symptoms; no standard…”
Get full text

Personalized treatment according to geriatric assessment in first-line recurrent and/or metastatic (R/M) head and neck squamous cell cancer (HNSCC) patients aged 70 or over: ELAN (ELderly heAd and Neck cancer) FIT and UNFIT trials by Guigay, J., Auperin, A., Mertens, C., Even, C., Geoffrois, L., Cupissol, D., Rolland, F., Sire, C., Fayette, J., Peyrade, F., Blot, E., Debourdeau, P., Bozec, L., Capitain, O., Pointreau, Y., Brard, C., Michel, C., Schwob, D., Ortholan, C., Le Caer, H.

Get full text

1110O - Personalized treatment according to geriatric assessment in first-line recurrent and/or metastatic (R/M) head and neck squamous cell cancer (HNSCC) patients aged 70 or over: ELAN (ELderly heAd and Neck cancer) FIT and UNFIT trials by Guigay, J., Auperin, A., Mertens, C., Even, C., Geoffrois, L., Cupissol, D., Rolland, F., Sire, C., Fayette, J., Peyrade, F., Blot, E., Debourdeau, P., Bozec, L., Capitain, O., Pointreau, Y., Brard, C., Michel, C., Schwob, D., Ortholan, C., Le Caer, H.

“…The main challenges in patients (pts)>= 70y are to cope with the treatment benefit/risk ratio and tumor related symptoms; no standard systemic treatment has…”
Get full text